46322-66-1 Usage
General Description
HydrazinecarboxiMidaMide,2-[(2,4-dichlorophenyl)Methylene], also known as procarbazine, is a chemical compound used primarily in the treatment of Hodgkin's disease and certain types of brain tumors. It belongs to the class of alkylating agents, which work by damaging the DNA of cancer cells, preventing them from growing and dividing. Procarbazine is typically administered in combination with other chemotherapy drugs to increase its effectiveness. Although it can be an effective treatment for certain types of cancer, it may also cause a range of side effects including nausea, vomiting, decreased blood cell counts, and an increased risk of infection. It is important for patients receiving procarbazine to be closely monitored by their healthcare provider for any adverse reactions or complications.
Check Digit Verification of cas no
The CAS Registry Mumber 46322-66-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 4,6,3,2 and 2 respectively; the second part has 2 digits, 6 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 46322-66:
(7*4)+(6*6)+(5*3)+(4*2)+(3*2)+(2*6)+(1*6)=111
111 % 10 = 1
So 46322-66-1 is a valid CAS Registry Number.
46322-66-1Relevant articles and documents
Synthesis, Antileishmanial Activity and In Silico Studies of Aminoguanidine Hydrazones (AGH) and Thiosemicarbazones (TSC) Against Leishmania chagasi Amastigotes
Alexandre-Moreira, Magna S.,Aquino, Pedro G. V.,Bourguignon, Jean-Jacques,Bri-Card, Jacques,Freitas, Johnnatan D.,Meneghetti, Mario R.,Nascimento, Igor J. S.,Queiroz, Aline C.,Rodrigues, Klinger A. F.,Rodrigues, Raiza R. L.,Santos, Mariana S.,Schmitt, Martine,de Aquino, Thiago M.,Araújo, Morgana V.,Fran?a, Paulo H. B.,Rodrigues, érica E. E. S.,Santos-Júnior, Paulo F. S.,da Silva-Júnior, Edeildo F.,de Araújo-Júnior, Jo?o X.
, p. 151 - 169 (2022/02/05)
Background: Leishmaniasis is a worldwide health problem, highly endemic in developing countries. Among the four main clinical forms of the disease, visceral leishmaniasis is the most se-vere, fatal in 95% of cases. The undesired side-effects from first-li
